Company Encyclopedia
View More
name
TSZY
002872.SZ
Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, digestive, cardiovascular and cerebrovascular, pediatric, gynecological, orthopedic, oncology, hepatobiliary, blood, surgery, diabetes, and others. The company was founded in 2001 and is based in Chongqing, China.
3.165 T
002872.SZMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking220/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.80%D
    • Profit Margin-18.67%D
    • Gross Margin54.48%B
  • Growth ScoreD
    • Revenue YoY-10.28%D
    • Net Profit YoY-102.50%E
    • Total Assets YoY-4.56%D
    • Net Assets YoY-4.37%D
  • Cash ScoreE
    • Cash Flow Margin-535.49%E
    • OCF YoY-10.28%D
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreB
    • Gearing Ratio25.64%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST TSZY: The company is not involved in the photovoltaic industry

    36Kr learned that on November 6th, ST Tian Sheng stated on the interactive platform that the company's main business is pharmaceutical manufacturing and does not involve the photovoltaic industry

    36Kr·
    SZ
    002872
    -0.20%
    36Kr·
    SZ
    002872
    -0.20%

    ST TSZY: Wholly-owned subsidiary plans to be selected for the continued procurement of drugs such as Guangdong Alliance Diclofenac

    ST TSZY announced that its wholly-owned subsidiaries Hubei Tiansheng and Hunan Tiansheng participated in the continuous procurement of drugs such as sodium chloride injection and clindamycin hydrochloride injection in Guangdong Alliance. The products intended for selection include concentrated sodium chloride injection and clindamycin hydrochloride injection, among others. This will help expand the sales range and increase market share, but the procurement contract has not yet been signed, and the subsequent impact remains uncertain

    Zhitong·
    SZ
    002872
    -0.20%
    Zhitong·
    SZ
    002872
    -0.20%

    ST Tian Sheng provides joint liability guarantee for subsidiary's loan of 10 million

    ST TSZY provides a guarantee for its wholly-owned subsidiary Hubei TSZY to apply for credit from the bank, signing a loan contract for 10 million yuan in working capital. ST TSZY provides a joint liability guarantee for this loan, covering both principal and interest, with a guarantee period of three years. As of June 30, 2025, Hubei TSZY has total assets of 224.9254 million yuan, with no overdue or litigated guarantees

    Zhitong·
    SZ
    002872
    -0.20%
    Zhitong·
    SZ
    002872
    -0.20%

    ST TSZY: Sodium Bicarbonate Injection passes the consistency evaluation of generic drugs

    ST TSZY's wholly-owned subsidiary Hubei TSZY Pharmaceutical recently received approval from the National Medical Products Administration, with sodium bicarbonate injection passing the consistency evaluation for generic drugs. This medication is primarily used for the nonspecific treatment of metabolic acidosis, alkalinizing urine, and certain drug overdoses. This move will enhance the market competitiveness of the drug and accumulate experience for the consistency evaluation of generic drugs for the company's other products

    Zhitong·
    SZ
    002872
    -0.20%
    Zhitong·
    SZ
    002872
    -0.20%

    ST Tian Sheng: Net loss of 36.7123 million yuan in the first half of 2025, a year-on-year narrowing of 14.84%

    ST Tian Sheng announced that its operating income in the first half of 2025 was 232 million yuan, a year-on-year decrease of 17.49%. The net loss was 36.7123 million yuan, a year-on-year narrowing of 14.84%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through the conversion of reserves

    Zhitong·
    SZ
    002872
    -0.20%
    Zhitong·
    SZ
    002872
    -0.20%
    © 2025 Longbridge｜Disclaimer